Home › Companies › VTVT

vTv Therapeutics Inc.

VTVT Rare disease Lead: Phase 3 4 Biotech Distilled articles ↓

Metabolic Respiratory Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (8 active programs)

cadisegliatin

TTP399

Small Molecule Target: glucokinase

Type 1 Diabetes Phase 3 oral
Type 2 Diabetes Phase 2 oral G42 Investments

TTP273

Small Molecule Target: GLP-1 receptor

Cystic Fibrosis-Related Diabetes Phase 2 oral
Type 2 Diabetes Phase 2 oral

TTP-RA

Small Molecule Target: RAGE

Type 1 Diabetes Preclinical oral

mavodelpar

HPP593 · REN001

Small Molecule Target: PPAR-delta

Undisclosed indication

HPP971

Small Molecule Target: Nrf2, Bach1

Undisclosed indication Phase 1

HPP737

Small Molecule Target: PDE4

Undisclosed indication oral Newsoara Biopharma

Biotech Distilled coverage (4)

2026-05-14 UPDATE: vTv Therapeutics (VTVT) – The ATM Refresh on Earnings Day 🔒 Paid
2026-03-29 UPDATE: vTv Therapeutics (VTVT) - Smart Money Buys the Delay
2026-03-14 UPDATE: vTv Therapeutics (VTVT) – A Biotech Delay Hits Phase 3 🔒 Paid
2026-02-04 vTv Therapeutics (VTVT): Scientific Deep Dive for Cadisegliatin and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.